BCL9 and hepatocellular carcinoma: Yang et al. (41) showed that miR-1301 could reduce the Wnt/β-catenin signaling pathway by targeting BCL9, thereby inhibiting the metastasis, invasion and angiogenesis of hepatocellular carcinoma (HCC), which might be a therapeutic target for HCC.